drugset / Trial / NCT06543836
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The efficacy of combining TKI with PD-1 inhibitor in the treatment of advanced MSS/pMMR colorectal cancer with low levels of maxVAF in peripheral blood ctDNA failed with standard treatment was assessed, compared to standard treatment as chosen by researchers.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2025-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fruquintinib | Small molecule | 5 mg | — |
| Comparator | Regorafenib | Small molecule | 160 mg | — |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | — |